Financial Performance - The company achieved operating revenue of ¥405,501,949.74, an increase of 19.62% compared to the previous year[3] - The total profit reached ¥71,916,721.41, reflecting a growth of 41.53% year-on-year[3] - Net profit attributable to shareholders was ¥62,730,981.38, up 46.39% from the previous year[3] - The net profit after deducting non-recurring gains and losses was ¥63,315,536.88, representing a 53.23% increase year-on-year[3] - Basic earnings per share rose to ¥0.81, a 47.27% increase compared to the previous year[3] Assets and Equity - Total assets at the end of the reporting period were ¥889,388,272.66, a growth of 10.63% from the beginning of the period[4] - Shareholders' equity attributable to the company increased to ¥710,073,877.18, up 7.51% from the beginning of the period[4] Revenue Drivers - The company's three main business segments contributed to revenue growth: vaccine culture media, food nutrition products, and raw materials[6] - Profit growth was driven by steady revenue increase, cost structure optimization, and improved operational efficiency[7] Financial Data Disclaimer - The company warns that the financial data presented is preliminary and subject to change upon final audit[8]
无锡晶海(920547) - 2025 Q4 - 年度业绩